Pfizer exits Chinese generic drugs JV, Hisun-Pfizer Pharmaceuticals

In a significant shift within the pharmaceutical industry, Pfizer Inc. has announced its decision to exit the Hisun-Pfizer Pharmaceuticals joint venture by divesting its 49% stake to Sapphire I (HK) Holdings. The deal, for which the terms were not disclosed, marks the end of Pfizer’s involvement in the Chinese generic drugs market through this joint venture established in 2012 with Zhejiang Hisun Pharmaceuticals, a Shanghai-listed company.

Background and Development of Hisun-Pfizer Pharmaceuticals

Hisun-Pfizer Pharmaceuticals was formed to develop, manufacture, and commercialize branded generic pharmaceutical products both within China and internationally. Over the years, it has built a portfolio that includes a variety of generic medications, contributing significantly to the healthcare landscape in China.

Implications of the Divestiture

With Pfizer’s exit, Hisun-Pfizer Pharmaceuticals will undergo a renaming but will retain the rights to continue manufacturing, selling, and distributing all currently marketed and pipeline products in China. This move allows Pfizer to concentrate more on its core strengths and strategic interests, particularly in its primary markets and innovation-driven sectors.

Continued Collaboration and Support

Despite the divestiture, Pfizer is not stepping away entirely from supporting Hisun-Pfizer Pharmaceuticals. The American pharmaceutical giant will continue to provide global manufacturing expertise, including manufacturing, technical, and regulatory support services. This ongoing support underscores Pfizer’s commitment to ensuring the stability and quality of the joint venture’s product offerings during and after the transition.

Additionally, to facilitate a smooth transition, Pfizer will continue to supply selected products to the Chinese generic drug company for a defined period after the closing of the transaction.

Future Prospects for Hisun and Pfizer

This strategic realignment allows Hisun to fully leverage its capabilities in the generics market while Pfizer refocuses its resources on higher-growth areas. The sustained collaboration between Pfizer and Hisun aims to ensure that essential generic pharmaceuticals remain accessible to patients across China, maintaining a vital supply chain and support system.

Pfizer’s exit from the Hisun-Pfizer joint venture represents a significant realignment of its business strategy in China, reflecting broader trends in the global pharmaceutical industry where companies continue to adapt to dynamic market conditions and focus on core business areas.